5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole
• 英文别名: 5-cyclohexyloxy-3-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-1-(3-nitrophenyl)sulfonylindole
• 化学式: C₂₆H₂₉N₃O₅S
• 分子量: 495.599
• InChiKey: UEISPMVVZNJELF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  106
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole 、 3-硝基苯磺酰氯 生成 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole
  参考文献：
  名称：

  Piperidine-indole compounds having 5-HT.sub.6 affinity

  摘要：

  本文描述了与5-HT.sub.6受体亲和力的化合物，其具有以下一般公式：其中：R.sup.1选自H和C.sub.1-4烷基组; R.sup.2选自H、C.sub.1-4烷基和苄基组; -- -- --代表单键或双键; R.sup.3选自COR.sup.5和SO.sub.2R.sup.5组; R.sup.4a选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基组; R.sup.4b选自H、羟基、卤素、C.sub.3-7环烷氧基、C.sub.1-4烷氧基、C.sub.1-4烷基、苄氧基、苯氧基、三氟甲基、三氟甲氧基和乙烯基组; R.sup.4c选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基组; R.sub.4d选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基组; R.sup.5选自苯基、吡啶基、噻吩基、喹啉基和萘基，可选择地用1-4个来自C.sub.1-4烷氧基、C.sub.1-4烷基、卤素、硝基、三氟甲基、三氟甲氧基、1,2-亚甲二氧基、C.sub.1-4烷基羰基、C.sub.1-4烷氧羰基和C.sub.1-4烷基硫代基的取代基取代。还描述了将这些化合物用作药物治疗5-HT.sub.6受体受抑制相关的适应症，如精神分裂症。

  公开号：

  US06133287A1

文献信息

• PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY
  申请人：NPS Allelix Corp.

  公开号：EP1173432B9

  公开（公告）日：2008-10-15
• US6133287A
  申请人：——

  公开号：US6133287A

  公开（公告）日：2000-10-17
• [EN] PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY<br/>[FR] COMPOSES PIPERIDINE-INDOL AYANT UNE AFFINITE AVEC 5-HT6
  申请人：ALLELIX BIOPHARMA

  公开号：WO2000063203A1

  公开（公告）日：2000-10-26

  Described herein are indole compounds with affinity for the 5-HT6 receptor, which have general formula (I) wherein, R1 is selected from the group consisting of H and C¿1-4?alkyl; R?2¿ is selected from the group consisting of H, C¿1-4?alkyl and benzyl; ----- represents a single or double bond; R?3¿ is selected from the group consisting of COR5 and SO¿2?R?5; R4a¿ is selected from the group consisting of H, OH, halo, C¿1-4?alkyl and C1-4alkoxy; R?4b¿ is selected from the group consisting of H, hydroxy, halo, C¿3-7?cycloalkyloxy, C1-4alkoxy, C1-4alkyl, benzyloxy, phenoxy, trifluoromethyl, trifluoromethoxy and vinyl; R?4c¿ is selected from the group consisting of H, OH, halo, C¿1-4?alkyl and C1-4alkoxy; R?4d¿ is selected from the group consisting of H, OH, halo, C¿1-4?alkyl and C1-4alkoxy; and R?5¿ is selected from the group consisting of phenyl, pyridyl, thienyl, quinolinyl and naphthyl which are optionally substituted with 1-4 substituents selected from C¿1-4?alkoxy, C1-4alkyl, halo, nitro, trifluoromethyl, trifluoromethoxy, 1,2-methylenedioxy, C1-4alkylcarbonyl, C1-4alkoxycarbonyl and C1-4alkylS-. Also described is the use of the compounds as pharmaceuticals to treat indications where inhibition of the 5-HT6 receptor is implicated, such as schizophrenia.
• Piperidine-indole compounds having 5-HT.sub.6 affinity
  申请人：Allelix Biopharmaceuticals Inc.

  公开号：US06133287A1

  公开（公告）日：2000-10-17

  Described herein are compounds with affinity for the 5-HT.sub.6 receptor, which have the general formula: wherein: R.sup.1 is selected from the group consisting of H and C.sub.1-4 alkyl; R.sup.2 is selected from the group consisting of H, C.sub.1-4 alkyl and benzyl; -- -- -- represents a single or double bond; R.sup.3 is selected from the group consisting of COR.sup.5 and SO.sub.2 R.sup.5 ; R.sup.4a is selected from the group consisting of H, OH, halo, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; R.sup.4b is selected from the group consisting of H, hydroxy, halo, C.sub.3-7 cycloalkyloxy, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, benzyloxy, phenoxy, trifluoromethyl, trifluoromethoxy and vinyl; R.sup.4c is selected from the group consisting of H, OH, halo, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; R.sub.4d is selected from the group consisting of H, OH, halo, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; and R.sup.5 is selected from the group consisting of phenyl, pyridyl, thienyl, quinolinyl and naphthyl which are optionally substituted with 1-4 substituents selected from C.sub.1-4 alkoxy, C.sub.1-4 alkyl, halo, nitro, trifluoromethyl, trifluoromethoxy, 1,2-methylenedioxy, C.sub.1-4 alkylcarbonyl, C.sub.1-4 alkoxycarbonyl and C.sub.1-4 alkylS--. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT.sub.6 receptor is implicated, such as schizophrenia.

  本文描述了与5-HT.sub.6受体亲和力的化合物，其具有以下一般公式：其中：R.sup.1选自H和C.sub.1-4烷基组; R.sup.2选自H、C.sub.1-4烷基和苄基组; -- -- --代表单键或双键; R.sup.3选自COR.sup.5和SO.sub.2R.sup.5组; R.sup.4a选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基组; R.sup.4b选自H、羟基、卤素、C.sub.3-7环烷氧基、C.sub.1-4烷氧基、C.sub.1-4烷基、苄氧基、苯氧基、三氟甲基、三氟甲氧基和乙烯基组; R.sup.4c选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基组; R.sub.4d选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基组; R.sup.5选自苯基、吡啶基、噻吩基、喹啉基和萘基，可选择地用1-4个来自C.sub.1-4烷氧基、C.sub.1-4烷基、卤素、硝基、三氟甲基、三氟甲氧基、1,2-亚甲二氧基、C.sub.1-4烷基羰基、C.sub.1-4烷氧羰基和C.sub.1-4烷基硫代基的取代基取代。还描述了将这些化合物用作药物治疗5-HT.sub.6受体受抑制相关的适应症，如精神分裂症。